You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 7,906,626

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,906,626

Title:	Immunological control of .beta.-amyloid levels in vivo
Abstract:	Disclosed are bispecific antibodies comprising a first antibody binding specificity which confers the ability of the bispecific antibody to cross the blood-brain barrier, and a second antibody specificity conferring the ability of the bispecific antibody to bind to a .beta.-amyloid epitope. Also disclosed are methods for inhibiting the formation of .beta.-amyloid plaques in the brain of a human, or promoting the disaggregation of a preformed .beta.-amyloid plaque. Such methods recite the administration of a bispecific antibody.
Inventor(s):	Raso; Victor (Brighton, MA)
Assignee:	Boston Biomedical Research Institute (Watertown, MA)
Application Number:	11/063,350
Patent Claims:	1. A therapeutic antibody that specifically binds and cleaves an epitope contained within amino acid positions 10-25 of .beta.-amyloid, wherein said antibody binds soluble .beta.-amyloid and soluble .beta.-amyloid aggregates in a living organism. 2. The therapeutic antibody of claim 1 that is a whole antibody. 3. The therapeutic antibody of claim 1 that specifically binds to an epitope having an amino acid between positions 14 and 25 of .beta.-amyloid. 4. The therapeutic antibody of claim 1, which specifically binds an epitope contained in positions 14 -25 of said .beta.-amyloid peptide. 5. An antibody fragment that specifically binds and cleaves an epitope contained within amino acid positions 10-25 of .beta.-amyloid, wherein said antibody binds soluble .beta.-amyloid and soluble .beta.-amyloid aggregates in a living organism. 6. The fragment of claim 5, which is a Fab or F(ab').sub.2 fragment. 7. The fragment of claim 6 which is an F(ab').sub.2 fragment. 8. The fragment of claim 6, which is an Fab fragment. 9. The therapeutic antibody of claim 1, wherein the antibody is produced in a myeloma cell. 10. A composition that comprises the antibody of claim 1, and a sterile diluent.

Details for Patent 7,906,626

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2019-06-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.